CIK 0000874015 · Large accelerated filer
IONIS PHARMACEUTICALS INC
Sign in to watch- Ticker
- IONS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 330336973
- Phone
- 7609319200
- Business address
- 2855 GAZELLE COURT, CARLSBAD, CA, 92010
- Former names
- ISIS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $148,200
- in 1 filing
- Open-market sales, last 90 days
- $61,389
- in 2 filings
Net +$86,811. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Sale 10b5-1 | −20,000 | $82.60 | $1.7M | 80,293 |
| 2026-02-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Option exercise 10b5-1 | +48,626 | $60.89 | $3.0M | 128,919 |
| 2026-02-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Sale 10b5-1 | −48,626 | $83.03 | $4.0M | 80,293 |
| 2026-02-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Option exercise 10b5-1 | +16,463 | $32.60 | $537K | 96,756 |
| 2026-02-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Sale 10b5-1 | −16,463 | $83.03 | $1.4M | 80,293 |
| 2026-02-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −16,463 | 2,406 | ||
| 2026-02-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −48,626 | 0 | ||
| 2026-01-30 | Swayze Eric EVP Research | Sale | −6,179 | $82.93 | $512K | 47,747 |
| 2026-01-30 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Sale | −6,179 | $83.45 | $516K | 69,702 |
| 2026-01-30 | O'NEIL PATRICK R. EVP CLO & General Counsel | Sale | −6,179 | $83.53 | $516K | 71,983 |
| 2026-01-30 | Monia Brett P Chief Executive Officer | Sale | −62,970 | $82.72 | $5.2M | 283,927 |
| 2026-01-30 | HOUGEN ELIZABETH L EVP, Finance & CFO | Sale | −6,988 | $83.24 | $582K | 132,881 |
| 2026-01-30 | Birchler Brian EVP, Corp and Development Ops | Sale | −6,179 | $83.03 | $513K | 66,247 |
| 2026-01-30 | BENNETT C FRANK EVP, Chief Scientific Officer | Sale | −5,885 | $82.95 | $488K | 100,293 |
| 2026-01-30 | Baroldi Joseph EVP, Chief Business Officer | Sale | −5,296 | $82.96 | $439K | 45,413 |
| 2026-01-29 | Swayze Eric EVP Research | Grant or award | +11,991 | 53,926 | ||
| 2026-01-29 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Grant or award | +11,991 | 75,881 | ||
| 2026-01-29 | O'NEIL PATRICK R. EVP CLO & General Counsel | Grant or award | +11,991 | 78,162 | ||
| 2026-01-29 | Monia Brett P Chief Executive Officer | Grant or award | +122,214 | 346,897 | ||
| 2026-01-29 | HOUGEN ELIZABETH L EVP, Finance & CFO | Grant or award | +13,562 | 139,869 |
Page 12 of 18 · 360 trades